Drug Trial Radar · NCT04815148
MH004 Topical Cream in Healthy Adult Volunteers and Participants With Atopic Dermatitis or Rheumatoid Arthritis
Last checked: Nov 19, 2026Latest source record: Mar 24, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
72
Planned (sponsor's estimate)
Start
Apr 1, 2021
Primary completion
Mar 31, 2022
Study completion Mar 31, 2022
Sponsor
- Lead sponsor
- Minghui Pharmaceutical Pty LtdIndustry
- Sponsor type
- Industry
- First posted
- Mar 24, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase Ia/Ib Study of MH004 in Healthy Adult Volunteers, participants with Mild to Moderate Atopic Dermatitis and participants with Mild to Moderate Rheumatoid Arthritis.
Conditions
- Atopic Dermatitis
- Rheumatoid Arthritis
Interventions
MH004 Ia(0.1%)Drug
Spread approx. 1 g of MH004 topical cream to the upper thigh skin.
MH004 Ia(0.3%)Drug
Spread approx. 1 g of MH004 topical cream to the upper thigh skin.
MH004 Ia(1%)Drug
Spread approx. 1 g of MH004 topical cream to the upper thigh skin.
MH004 Ia(3%)Drug
Spread approx. 1 g of MH004 topical cream to the upper thigh skin.
MH004 Ib-1(0.1%)Drug
Spread approx. 0.5 g of MH004 topical cream to the area of Target AD Lesions.
MH004 Ib-1(0.3%)Drug
Spread approx. 0.5 g of MH004 topical cream to the area of Target AD Lesions.
MH004 Ib-1(1%)Drug
Spread approx. 0.5 g of MH004 topical cream to the area of Target AD Lesions.
MH004 Ib-2(0.3%)Drug
Spread approx. 0.5 g of MH004 topical cream to the Target Joint.
MH004 Ib-2(1%)Drug
Spread approx. 0.5 g of MH004 topical cream to the Target Joint.
MH004 Ib-2(3%)Drug
Spread approx. 0.5 g of MH004 topical cream to the Target Joint.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the incidence and severity of Treatment-Emergent Adverse Events [Safety and Tolerability].Time frame: 1 year
- To determine the maximum tolerated dose (MTD) of MH004 topical cream.Time frame: 1 year
- To establish the recommended phase 2 dose (RP2D).Time frame: 1 year
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.